Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalvista Pharmaceuticals Inc

12.60
+0.35002.86%
Post-market: 13.370.7700+6.11%19:54 EDT
Volume:437.53K
Turnover:5.44M
Market Cap:622.67M
PE:-3.45
High:12.63
Open:12.25
Low:11.96
Close:12.25
Loading ...

KalVista Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

KalVista Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
13 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Business Wire
·
10 Mar

Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a share - Earnings Preview

Reuters
·
07 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
04 Mar

KalVista Pharmaceuticals Price Target Maintained With a $19.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
03 Mar

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire
·
24 Feb

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
21 Feb

JMP Securities Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)

TIPRANKS
·
11 Feb

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
10 Feb

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
04 Feb

Why Pharvaris (PHVS) Is Advancing Today

Insider Monkey
·
01 Feb

KalVista Pharmaceuticals Initiated at Market Outperform by JMP Securities

Dow Jones
·
01 Feb